Several novel biotechnological advancements signal progress in diagnostics and treatments spanning oncology, immunology, and metabolic disorders. University of Chicago spinout OrisDx is preparing to launch a saliva-based next-gen sequencing assay by year-end for early detection of oral cancers, aiming to reduce unnecessary biopsies. Researchers at Kazakh National Agrarian Research University engineered an intranasal monoclonal antibody against mugwort pollen, effectively reducing allergic rhinitis and asthma symptoms in a mouse model. Additionally, Rhythm Pharmaceuticals reported promising Phase II data for bivamelagon, an oral MC4R agonist showing efficacy in hypothalamic obesity, and Antag Therapeutics anticipates imminent Phase I readouts for a novel GIP blockade drug candidate targeting obesity.